Mesa Laboratories Inc /Co/ (MLAB) Stock Price & Analysis
Mesa Laboratories Inc /Co/ (MLAB) rose 0.53% to USD 109.03 as of June 10, 2026 at 03:40 UTC, according to Nexqual real-time market data.
MLAB last closed at USD 108.46; the session ranged USD 105.68–113.99 on volume of 361,954 shares. Market capitalization is $602.38M, with a 52-week range of USD 55.45–113.99 (NMS). Source: Nexqual, June 10, 2026 at 03:40 UTC.
Key Statistics (as of June 10, 2026 at 03:40 UTC)
| Price | USD 109.03 |
|---|---|
| Change | ▲ 0.53% (up) |
| Previous Close | USD 108.46 |
| Open | USD 110.39 |
| Day Range | USD 105.68 – 113.99 |
| 52-Week Range | USD 55.45 – 113.99 |
| Volume | 361,954 shares |
| Market Cap | $602.38M |
| Exchange | NMS |
Technical Analysis (MLAB)
Nexqual's technical model rates MLAB "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:40 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.75 (neutral) |
| vs SMA50 | Above (USD 100.42) |
| MACD | 2.06 (positive) |
Analyst Ratings (MLAB)
Wall Street analysts rate MLAB "Buy" based on 2 analysts, with a mean price target of USD 112 (range USD 94–130), per Nexqual as of June 10, 2026 at 03:40 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 112 |
| High Target | USD 130 |
| Low Target | USD 94 |
| Buy / Hold / Sell | 1 / 2 / 0 |
Earnings (MLAB)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 2.55 |
| Revenue Estimate | $60.87M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.83 vs est 1.39 ▲ beat |
| 2025-12-31 | USD 1.76 vs est 1.47 ▲ beat |
| 2025-09-30 | USD 2.11 vs est 1.56 ▲ beat |
| 2025-06-30 | USD 1.88 vs est 2.16 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Financials & Fundamentals (MLAB)
| Total Revenue | $249.13M |
|---|---|
| Revenue Growth (YoY) | +2.60% |
| Gross Margin | +63.53% |
| Operating Margin | +4.31% |
| Profit Margin | +2.69% |
| ROE | +3.88% |
| Debt / Equity | 90.65 |
| Current Ratio | 1.72 |
| Total Cash | $28.57M |
| Total Debt | $168.83M |
| Free Cash Flow | $31.88M |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Financial Health Score (MLAB)
Nexqual rates Mesa Laboratories Inc /Co/'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:40 UTC.
| Growth | Mixed — Revenue +3.4% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 4% |
| Balance Sheet | Mixed — $29M cash vs $169M debt |
| Cash Flow | Solid — FCF $32M, 13% margin |
| Efficiency | Weak — ROE 4%, ROA 2.7% |
Ownership (MLAB)
| Insider Ownership | +5.55% |
|---|---|
| Institutional Ownership | +93.76% |
| Shares Outstanding | 5.52M |
| Float | 4.94M |
| Short % of Float | +7.38% |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Leadership (MLAB)
Mesa Laboratories Inc /Co/ is led by Siddhartha Chandrakant Kadia B.E., M.S. (age 55), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:40 UTC.
| CEO, President & Director | Siddhartha Chandrakant Kadia B.E., M.S. (age 55) |
|---|---|
| VP, CFO & Chief Accounting Officer | John V. Sakys (age 56) |
| Senior Vice President of Continuous Improvement | Brian David Archbold (age 50) |
Major Backers & Investors (MLAB)
Notable institutional backers of Mesa Laboratories Inc /Co/ include Long Path Partners LP, Boston Partners, Diamond Hill Capital Management Inc, according to Nexqual as of June 10, 2026 at 03:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Long Path Partners LP | 7.34% |
| Boston Partners | 4.86% |
| Diamond Hill Capital Management Inc | 4.85% |
| Select Equity Group LP | 4.27% |
| Ranger Investment Management, L.p. | 3.67% |
| AQR Capital Management, LLC | 3.09% |
| Morgan Stanley | 2.93% |
| Royce & Associates LP | 2.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.39% |
| Vanguard Group | 8.32% |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
From Mesa Laboratories Inc /Co/'s Latest SEC 10-K Filing (filed 2026-06-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
- The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
- This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries.
- The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UTMD | Utah Medical Products, Inc. | USD 68.07 | ▲ 0.62% |
| WINA | Winmark Corporation | USD 387.62 | ▲ 2.66% |
| OFLX | Omega Flex, Inc. | USD 31.18 | ▲ 3.42% |
| CASS | Cass Information Systems, Inc | USD 48.35 | ▲ 1.75% |
| PFIS | Peoples Financial Services Corp | USD 61.85 | ▲ 2.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:40 UTC. This page is informational and not investment advice.